EMA Application withdrawn: Docetaxel Mylan (docetaxel) — Mylan S.A.S.

View source ↗

Summary

Withdrawal of the EMA application for Docetaxel Mylan (docetaxel) by Mylan S.A.S., affecting multiple solid tumor indications including non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Neoplasms
• Head and Neck Neoplasms
• Non-small Cell Lung Cancer
• Prostatic Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Docetaxel Mylan (docetaxel)

Snippet

Status: Application withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Breast Neoplasms;Head and Neck Neoplasms;Stomach Neoplasms;Adenocarcinoma;Prostatic Neoplasms. MAH: Mylan S.A.S.. Decision date: 26/04/2010